Healx is a Cambridge, UK-based company passionate about finding new therapeutic solutions for rare diseases. The company uses advanced data analytics, including machine learning and modern computational biology techniques to identify novel drug applications in the area of rare disorders.
Their unique model places patient advocacy groups at the heart of the drug discovery process, leading the way to personalized medicine for rare diseases.
Listed in 2017 as a ‘Leading Global Innovator’ in Disrupt 100 and awarded ‘Cambridge Graduate Startup of the Year’ in 2016, Healx is considered as one of the leading startups of the Cambridge cluster.
In the media
16th October 2019
Healx secures $56m in Series B financing, launches global accelerator programme for rare diseases
9th July 2020
AI In Drug Discovery Market Research Report 2020-2027: By Product, Application, Manufacturer, Sales and Segmentation
Some of the companies operating in this aspect are BioXcel Therapeutics, Healx, and few others. De novo Drug Designing: Drug designing is a critical process where one has to consider the
8th July 2020
Tech Nation Talks East of England: ‘Futurecorns’ developing tomorrow’s tools
Power of the mission Healx , which develops AI-powered biotech to discover new treatments for rare diseases, secured $56m (around £49m) in a Series B round in October last